Tag: Motley Fool

  • Warren Buffett: the 3 vital investing rules the world’s best investor follows

    Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett

    Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett

    Warren Buffett.

    The name alone causes most investors to drop whatever else they’re doing and pay attention.

    And for good reason.

    Warren Buffett notched up his first billion dollars back in the 1980s. And as the chairman and CEO of Berkshire Hathaway, he’s continued to build on that wealth since.

    For many years now, he’s been counted not just as one of the world’s richest people but also as one of the all-time greatest investors.

    And the Oracle of Omaha isn’t one to keep his investment strategies to himself. He readily shares his wisdom on how he’s managed to achieve outsized returns in interviews and videos.

    Below we look at three vital investing rules Warren Buffett swears by.

    Patience is a virtue Warren Buffett advises

    We’d all like to think we can somehow time the stock market. That we may know something most investors don’t.

    But the reality is timing the market correctly is incredibly difficult, even for seasoned investors. And we don’t know of any investors who’ve managed to do so consistently over the long term.

    Which is why Warren Buffett says, “The stock market is designed to transfer money from the active to the patient.”

    That means not jumping into a company’s stock simply because it’s getting a lot of media attention. If the price is too high, it’s best to be patient and wait for it to come down to a fair value.

    Similarly, when share markets come under pressure, as we saw in much of 2022 amid soaring inflation, your portfolio may lose value. Here again, patience is advised as, historically, stock markets have always recouped past losses and marched higher over time.

    Stay with what you know

    A second golden investing rule that’s helped Warren Buffett amass his billions is investing only in companies and sectors he’s familiar with.

    This has seen Buffett avoid the likes of cryptocurrencies and tech stocks. While that may have cost him some profits in the low interest rate boom times, it’s also saved him some hefty losses over the past year.

    That’s not to say everyone should avoid tech stocks. Far from it. But according to the Oracle of Omaha, you should only invest in a sector or company if you understand how it works.

    We all have our different areas of expertise. Sticking to investing within those areas can give you an edge over other investors who are outside their comfort zones.

    Warren Buffett: look for real value

    The best investments, Warren Buffet advises, provide real-world value, not just market value.

    In other words, don’t get sucked into the trap of buying shares that are the market darlings of the hour. You may find you’ve bought close to the medium-term highs and then find yourself selling at a loss.

    That’s why Buffett looks for companies that offer real-world value, with great brands and the ability to control prices.

    A bit of research on the past few years of financial results should give you a good grasp on the health of a company’s balance sheet and whether they’re likely to deliver consistent profits in the years ahead.

    The post Warren Buffett: the 3 vital investing rules the world’s best investor follows appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now…

    See The 5 Stocks
    *Returns as of December 1 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Berkshire Hathaway. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended the following options: long January 2023 $200 calls on Berkshire Hathaway, short January 2023 $200 puts on Berkshire Hathaway, and short January 2023 $265 calls on Berkshire Hathaway. The Motley Fool Australia has recommended Berkshire Hathaway. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/QStbd3c

  • Bell Potter names the ASX healthcare shares to buy in 2023

    Five healthcare workers standing together and smiling.

    Five healthcare workers standing together and smiling.

    If you’re interested in adding some healthcare sector exposure to your portfolio, then it could be worth taking a look at what Bell Potter is recommending.

    It has named its top picks in the healthcare sector for 2023 and the two ASX healthcare shares named below are on the list.

    Here’s what the broker is saying about these shares:

    PolyNovo Ltd (ASX: PNV)

    This medical device company is an ASX healthcare share to buy according to Bell Potter. Its analysts currently have a buy rating and $2.30 price target on its shares. This compares to the latest PolyNovo share price of $2.04.

    Its analysts believe a recent capital raising leaves PolyNovo well-placed for growth. It commented:

    The key offering of Polynovo is the proprietary biodegradable temporising matrix (BTM) that is utilised in the management of complex wounds and severe burns. The recent $33m capital raising in November 2022 provides the growth platform to facilitate expansion of the US and global sales team with key markets in Asia & Canada being targeted. Product launch within Hong Kong and India has already taken place during 1H23 whilst entry into Japan/ China is planned through a distributor model. These new operating segments increase the addressable market especially in regions with a significant healthcare burden of burns and complex/trauma wounds.

    Telix Pharmaceuticals Ltd (ASX: TLX)

    Another ASX healthcare share to buy could be this radiopharmaceutical company. Its analysts currently have a buy rating and $9.00 price target on its shares. This is notably higher than the current Telix share price of $6.97.

    The broker is expecting Telix’s Illuccix product to generate material revenue in 2023. It also remains optimistic on its clinical trials. The broker explained:

    We retain TLX as a key pick following very strong execution of its US business plan over recent months. Revenues from the sale of Illuccix continue to grow each quarter and the product is now expected to generate in excess of $300m in revenues in 2023. In the clinic, TLX 101 has generated positive trial data for the treatment of glioblastoma and TLX 250CDx reported positive data from its pivotal study for the imaging of clear cell renal carcinoma. The product is now expected to become the company’s second on market in late calendar year 2023. Telix remains well capitalised with $117m in cash at 30 September 2022 and based on our forecast, is expected to generate its maiden profit in CY2023.

    The post Bell Potter names the ASX healthcare shares to buy in 2023 appeared first on The Motley Fool Australia.

    FREE Investing Guide for Beginners

    Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…

    For over a decade, we’ve been helping everyday Aussies get started on their journey.

    And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.

    Yes, Claim my FREE copy!
    *Returns as of November 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/MeOoaL9

  • 3 ASX All Ordinaries shares defying today’s downturn to rocket higher

    Three businesspeople leap high with the CBD in the background.Three businesspeople leap high with the CBD in the background.

    The new year is off to a disastrous start for the All Ordinaries Index (ASX: XAO) and most of the shares that call it home.

    Despite posting a strong start to Tuesday’s session ­– it jumped as high as 0.47% in early trade – the benchmark index tumbled to a two-month low this afternoon.

    Right now, the All Ordinaries is down 1.62% at 7,104.7 points.

    Fortunately, though, not all its constituents are suffering. We’ve rounded up three that are posting gains of as much as 7%. Let’s take a look.

    3 All Ordinaries shares posting whopping gains

    The first All Ordinaries share defying today’s tumble is Airtasker Ltd (ASX: ART). Stock in the online marketplace for services is leaping 2.9% to trade at 35.5 cents right now despite the company’s silence.

    Sadly, however, today’s gain hasn’t proven enough to boost the embattled share back into the long-term green. It’s fallen 75% since it floated on the ASX in March 2021.

    Next up is media and entertainment company HT&E Ltd (ASX: HT1). The All Ordinaries share is roaring 3.63% higher to swap hands for $1 apiece. Its gain comes on news of a major divestment.

    The company today revealed it’s agreed to sell its 25% stake in Soprano Design to Potentia Capital for around $66.3 million in cash.

    If the name Potentia rings any bells, it’s likely because it’s the private equity firm that recently put in so-far-unsuccessful bids for both Tyro Payments Ltd (ASX: TYR) and Nitro Software Ltd (ASX: NTO).

    Finally, the Neuren Pharmaceuticals Ltd (ASX: NEU) share price is rocketing 7.67% right now to trade at $8.56.

    That’s despite no news having been released by the All Ordinaries biopharmaceutical share.

    Today’s gain included, the stock is just 2.8% lower than the 15-year high it posted in November.

    The post 3 ASX All Ordinaries shares defying today’s downturn to rocket higher appeared first on The Motley Fool Australia.

    FREE Guide for New Investors

    Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…

    For over a decade, we’ve been helping everyday Aussies get started on their journey.

    And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.

    Yes, Claim my FREE copy!
    *Returns as of November 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Tyro Payments. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Airtasker. The Motley Fool Australia has recommended Tyro Payments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/El6iKPx

  • Why are ASX 200 lithium shares running on empty today?

    An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price fallsAn unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls

    Many ASX 200 lithium shares are in the red on the first day of new year trading.

    Pilbara Minerals Ltd (ASX: PLS) shares are down nearly 4% at the time of writing, while Core Lithium Ltd (ASX: CXO) is down 1.27%. Shares in Allkem Ltd (ASX: AKE) are currently trading 1.51% lower while Sayona Mining Ltd (ASX: SYA) shares are currently even with Friday’s closing price.

    Let’s take a closer look at what might be weighing on lithium stocks today.

    What’s going on?

    Materials shares are falling overall so far today, with the S&P/ASX 200 Materials Index (ASX: XMJ) down 1.13% at the time of writing. They’re performing better than the S&P/ASX 200 Index (ASX: XJO) which is down 1.67%.

    Lithium is an essential component in the use of electric vehicle (EV) batteries. News that EV giant Tesla delivered fewer vehicles than expected in 2022 could be weighing on demand sentiment today.

    Overnight, Tesla announced it delivered 405,278 electric vehicles in the fourth quarter of 2022. Overall in 2022, EV deliveries grew 40% year on year to 1.31 million.

    However, this fell short of the company’s goal to lift deliveries by 50%, Bloomberg reported. Also, analysts had been tipping Tesla to deliver 420,760 vehicles during the quarter. Bernstein analyst Toni Sacconaghi said (as cited by Bloomberg):

    We believe that Tesla is facing a significant demand problem. We believe Tesla will need to either reduce its growth targets (and run its factories below capacity) or sustain and potentially increase recent price cuts globally, pressuring margins.

    Meanwhile, economic data out of China could also be weighing on investors’ minds. Manufacturing in China slowed in December, Bloomberg reported. China makes 75% of all lithium-ion batteries, according to a December Australian Department of Industry report.

    In recent news, Core Lithium advised on Friday it has achieved the first shipment of 15,000 dry metric tonnes (dmt) of 1.4% Li2O. This achieved a price of US$951 per dmt. The ship will depart Darwin for Fancheng, China. Core Lithium CEO Gareth Manderson said:

    The first DSO shipment being loaded for export from the Darwin Port is another significant milestone for the company.

    Share price snapshot

    The Core Lithium share price has soared 70% in a year

     The Sayona Mining share price has jumped 44% in the last 52 weeks.

    Allkem shares have climbed 6% in a year.

    Pilbara shares have gained 12.5% in the past year.

    The post Why are ASX 200 lithium shares running on empty today? appeared first on The Motley Fool Australia.

    4 ways to prepare for the next bull market

    It’s a scary market. But staying in cash when inflation is surging likely won’t do investors any good either.

    And when some world-class companies have pulled back considerably from their recent highs… All while their fundamentals remain unchanged…

    It begs the question…

    Do you have these 4 stocks in your portfolio?

    See The 4 Stocks
    *Returns as of December 1 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Monica O’Shea has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/ecga8vr

  • Leading brokers name 3 ASX shares to buy today

    Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices

    Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices

    With most brokers taking a break over the holiday period, research notes are few and far between right now.

    But don’t worry because listed below are three recent broker buy recommendations that still have plenty of upside potential.

    Here’s why brokers think these ASX shares are in the buy zone:

    Life360 Inc (ASX: 360)

    According to a note out of Goldman Sachs, its analysts have a buy rating and $7.60 price target on this location technology company’s shares. Goldman believes that Life360 has ended the year positively, which it feels eases any risk to its FY 2022 guidance. In addition, the broker notes that the company’s subscription business trades at a discount to global subscription app peers when adjusting for its superior growth outlook. As a result, it sees scope for a re-rating in the future. The Life360 share price is trading at $4.85 today.

    Maas Group Holdings Ltd (ASX: MGH)

    Another note out of Goldman Sachs reveals that its analysts have a buy rating and $4.20 price target on this property, construction, and infrastructure solutions provider’s shares. Goldman highlights that Maas is in a transition phase that will see higher quality real estate income become the largest source of earnings in the next three years. And with Maas’ shares trading at 10x forward earnings, it believes there’s a lot of value on offer here. The Maas share price is fetching $2.58 today.

    Premier Investments Limited (ASX: PMV)

    Analysts at Macquarie have an outperform rating and $29.00 price target on this retail conglomerate’s shares. Macquarie has been impressed with the Smiggle and Peter Alexander owner’s strong start to the financial year. In fact, it highlights that the company’s sales growth is tracking ahead of its expectations. This led to Macquarie upgrading its earnings estimates for the year. The Premier Investments share price is trading at $24.57 on Tuesday.

    The post Leading brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now…

    See The 5 Stocks
    *Returns as of December 1 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor James Mickleboro has positions in Life360. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has recommended Premier Investments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/LUSiK9h

  • 2022 was strong for the NAB share price. What’s next?

    A bald man in a suit puts his hands around a crystal ball as though predictin the future.A bald man in a suit puts his hands around a crystal ball as though predictin the future.

    The National Australia Bank Ltd (ASX: NAB) share price managed to significantly outperform the S&P/ASX 200 Index (ASX: XJO) in 2022.

    Last year, the ASX 200 fell by around 7%, while NAB shares managed to deliver a positive gain of around 4%.

    How did the bank manage to deliver a positive performance? I’d suggest it may have been down to two key things.

    Positive run in 2022

    A key factor for the performance of the ASX bank share segment of the market is interest rates.

    The main profit generator for the Australian banking sector is lending. A change in the central bank interest rate can have widespread impact on the economy.

    There were several interest rate rates by the Reserve Bank of Australia (RBA) last year. The interest rate jumped from 0.1% to 3.10%.

    The lower official interest rate hurt bank lending margins, meaning their profitability was reduced. So, it would be logical for investors to think that higher interest rates can help lending margins.

    NAB said that in the second half of its FY22, it had a net interest margin (NIM) of 1.67%. But, the fourth quarter NIM was 1.72%, up 10 basis points on the third quarter. This could be promising for short-term profitability.

    Another factor that I think helped the ASX bank share in 2022 was that management has done a good job at turning the bank around and achieving growth.

    In the FY22 report, the company reported cash earnings growth of 8.3% to $7.1 billion. Excluding the Citi consumer business acquisition, revenue rose 7.8%, mainly reflecting higher volumes with growth of 7.3% (with housing lending up 5.6% and non-housing lending up 9.6%).

    NAB shares finished the 2022 financial year well capitalised, with a common equity tier 1 (CET1) ratio of 11.51%.

    What could 2023 bring for the NAB share price?

    The NAB CEO Ross McEwan referred to keeping “strong balance sheet settings”. McEwan said when he delivered the bank’s FY22 result:

    Maintaining these settings is important during the current economic uncertainty, with higher interest rates and higher inflation likely to challenge some customers. However, strong employment conditions along with substantial household and business savings give us confidence in the resilience of our customers and the broader economy.

    Our strategy is long term, and is not dependent on any particular operating environment or economic conditions. It is centred around an enduring ambition to improve the outcomes for our customers and colleagues. We have made good progress over the past two years which positions us well for a changing environment. However, there is more we can do. We will continue to remain focused on the disciplined execution of our strategy to support sustainable growth in earnings and shareholder returns over time.

    However, the bank has also outlined key considerations for FY23.

    It said that housing lending competitive pressures are “likely to intensify”, as well as the deposit mix headwind accelerating, further increasing funding costs.

    The NIM impact of RBA cash rate increases on unhedged deposits is “expected to peak” in the first half of FY23, with the estimated benefit of cash rate increases from October 2022 expected to be “lower”.

    So, the current monthly NIM that NAB is experiencing may be close to the best it is going to see during 2023. However, investors may also pay close attention to borrower arrears. If the higher interest rates mean some borrowers can’t afford their loans, then that could cause problems, leading to bad debts.

    If I had to guess, I wouldn’t be surprised if the NAB share price doesn’t move that much over 2023.

    The post 2022 was strong for the NAB share price. What’s next? appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now…

    See The 5 Stocks
    *Returns as of December 1 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/C6Sy3oQ

  • Why has the Core Lithium share price fallen 26% in a month?

    A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.

    The Core Lithium Ltd (ASX: CXO) share price has tumbled over the past month.

    Core Lithium shares have descended nearly 26% since market close on 2 December and are currently fetching $1.02. For perspective, the S&P/ASX 200 (ASX: XJO) has shed 4% in the last month.

    So what has been going on with the Core Lithium lately?

    What’s impacted Core Lithium in December?

    Core Lithium is not the only ASX lithium share that has fallen in the last month. Pilbara Minerals Ltd (ASX: PLS) shares have slid 26% in a month, while Sayona Mining Ltd (ASX: SYA) shares have lost 19%.

    Core Lithium shares plunged nearly 30% between market close on 2 December and 28 December before finishing the year on a high.

    A bearish note out of Goldman Sachs may have weighed on the company’s shares in early December. The broker put a sell rating on Core Lithium with a $1 price target. The commodity team at Goldman predicted lithium prices would start to fall in the second half of 2023. Analysts said:

    Our commodity team now expect lithium prices through 1H23 to reflect the near-term tightness and lagging spodumene contract price pass-through before declining over 2H23.

    Electric vehicle demand concerns, the performance of US lithium shares, and the lithium price also weighed on ASX lithium shares in December.

    The lithium carbonate price descended 15.6% from CNY 562,500 on 1 December to CNY 474,500 on 30 December.

    On the US market, Livent Corp (NYSE: LTHM) shares have shed 24% in the last month, while Sociedad Quimica y Minera de Chile (NYSE: SQM) shares have lost 16%.

    In positive news for Core Lithium in December, the team at Macquarie lifted its outlook on the Core Lithium share price to outperform with a $1.30 price target on the share price. This implies a 28% upside based on the current share price.

    Macquarie is optimistic about the company’s ability to generate bumper free cash flow in the 2024 and 2025 financial years.

    Core Lithium loaded the first shipment of 1.4% lithium oxide direct shipping ore from the Finniss mine on December 30. The ship containing 15,000 dmt of lithium oxide is bound for China from Darwin. Core Lithium shares soared nearly 6% on this day.

    Commenting on this news, CEO Gareth Manderson said:

    Core has made good progress during 2022 to transition from a mine developer to lithium producer. In 2023 we will continue this transition and the work required to build a quality operating business.”

    Core Lithium share price snapshot

    The Core Lithium share price has soared 73% in the past 52 weeks.

    Core Lithium has a market capitalisation of nearly $1.9 billion based on the current share price.

    The post Why has the Core Lithium share price fallen 26% in a month? appeared first on The Motley Fool Australia.

    FREE Investing Guide for Beginners

    Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…

    For over a decade, we’ve been helping everyday Aussies get started on their journey.

    And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.

    Yes, Claim my FREE copy!
    *Returns as of November 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Monica O’Shea has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/hlu0dmU

  • 3 pivotal moments you might have missed for CSL shares in 2022. What now?

    Two happy scientists analysing test results in a labTwo happy scientists analysing test results in a lab

    CSL Limited (ASX: CSL) shares endured a bumpy year in 2022, with the biotech company’s share price swaying between $240 and $305.

    When all was said and done, the CSL share price outperformed the S&P/ASX 200 Index (ASX: XJO) by approximately 6%. However, outperforming the benchmark wasn’t exactly a high bar to clear considering the index fell by nearly 7%.

    Here’s a look back at the key events for CSL shares in 2022.

    Funding secured

    In a disappointing start to last year, CSL shares tumbled 18% in the first six weeks of trading in 2022, as shown below. This was a much more pronounced fall than the 5% retreat by the Aussie benchmark.

    Investors were on edge as the world grew more uncertain amid Russia’s invasion of Ukraine. Only a few weeks earlier, CSL had announced its intentions to acquire Swiss pharmaceutical company Vifor Pharma for A$16.4 billion.

    The weakened market sentiment cast doubt on whether CSL would still be able to raise the funds needed to acquire Vifor. Though, on 14 February 2022, the $750 million share purchase plan had been completed — attracting over $940 million worth of applications. Likewise, the company proceeded to raise $4 billion by issuing bonds in the United States debt market in April.

    Vifor enters the room

    Between June and August, CSL shares bounced back by around 15% as the acquisition of Vifor drew closer. On 2 August, shareholders were notified that the completion of the deal was slated to take place by 9 August.

    In light of the landmark deal, CSL managing director and CEO Paul Perreault said:

    Joining CSL, the Vifor business adds near-term value along with a clear path to long-term sustainable growth. It also adds an outstanding management team, along with a high-value and complementary portfolio of products and market-leading position in the nephrology and iron deficiency spaces.

    The acquisition of Vifor brings CSL’s products under development to 37 in total and increases its existing pipeline by 32%. Analysts have mostly praised the addition, giving CSL greater diversification in its offerings.

    New era for CSL shares

    The third and final pivotal moment for CSL shares in 2022 came when longstanding CEO Paul Perreault revealed his plans to retire in 2023.

    After 10 years at the helm of one of Australia’s largest companies, Perreault has passed the baton to chief operating officer Dr Paul McKenzie. Following the news in December, the CSL share price proceeded to slip 4.5% over the rest of the month.

    What could be ahead for CSL shares?

    The first line item of 2023 will likely be Perreault officially stepping down from his role in March. From here, the former CEO will act as a strategic advisor to the company for six months to allow a seamless transition.

    In terms of the CSL share price… Citi analysts are forecasting earnings per share (EPS) growth greater than 20% for FY23 and FY24. Hence, the Citi team has slapped a $340 price target on the biotech, representing approximately 19% upside from here.

    Similarly, Macquarie has a favourable view on CSL shares for the year ahead. According to the investment bank’s latest model portfolio, CSL holds the highest weighting at 8.3% and a price target of $343.

    The post 3 pivotal moments you might have missed for CSL shares in 2022. What now? appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now…

    See The 5 Stocks
    *Returns as of December 1 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/HXf6Odm

  • Seven West Media share price lifts off on new cricket announcement

    A woman looks back and cheers as she watches television.A woman looks back and cheers as she watches television.

    The Seven West Media Ltd (ASX: SWM) share price is marching higher on this first day of trading in 2023.

    Shares in the ASX-listed media company are up 3.8% in morning trade at 41 cents per share.

    This comes despite the broader market facing some headwinds today, with the All Ordinaries Index (ASX: XAO) down 1.0% at this same time.

    So, why is the Seven West Media share price defying the sell-off?

    What’s piquing ASX investor interest?

    The Seven West Media share price looks to be getting a boost after the company announced a new agreement with Cricket Australia.

    The new, seven-year deal extends Seven West’s media rights from the 2024-25 season to the 2030-31 season.

    The company said that its 7plus channel will become the “live and free home of cricket”, providing a digital package of rights atop the broadcast on its Seven Network. Seven West Media has never held digital rights to cricket before this agreement.

    Commencing in 2024, Seven West Media will see a 13% decrease in its media rights fees from its current agreement. The new agreement will see the media company pay $65 million in cricket media rights fees a year. SWM said that it has achieved cash savings from rights reduction and production savings of more than $50 million over the term compared to the existing rights deal.

    Cricket Australia has said it will reduce the number of Big Bash League (BBL) games to create a shorter tournament that will run for five to six weeks.

    Seven West and Cricket Australia had been involved in a legal stoush over prior contract issues. With the new agreement in place, both sides have agreed to drop the court proceedings, with each paying its own costs.

    Commenting on the agreement that looks to be sending the Seven West Media share price higher today, CEO James Warburton, said:

    We are delighted to extend our partnership with Cricket Australia until 2030-31. A comprehensive package of digital rights to the cricket for 7plus will ensure that for the first time, our viewers will be able to access cricket, live and free, in a way that suits them.

    Our combined broadcast and digital rights for both cricket and the AFL means Seven and 7plus will be the home of sport all year round… We look forward to working with Cricket Australia to grow Test cricket, women’s internationals and the BBL and WBBL in the years ahead.

    Seven West Media share price snapshot

    As you can see in the below chart, the Seven West Media share price came under pressure in 2022, falling almost 35%. With that year behind us, we imagine investors will be cheering a positive start to the new year.

    The post Seven West Media share price lifts off on new cricket announcement appeared first on The Motley Fool Australia.

    FREE Investing Guide for Beginners

    Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…

    For over a decade, we’ve been helping everyday Aussies get started on their journey.

    And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.

    Yes, Claim my FREE copy!
    *Returns as of November 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/QBJxPzX

  • Can these 2 ASX 200 shares crush the market again in 2023?

    A woman looks questioning as she puts a coin into a piggy bank.

    A woman looks questioning as she puts a coin into a piggy bank.Although the S&P/ASX 200 Index (ASX: XJO) tumbled a disappointing 5.5% in 2022, not all ASX 200 shares fell with the market.

    Two ASX 200 shares that crushed the market last year with gains of at least 20% were infant formula company A2 Milk Company Ltd (ASX: A2M) and airline operator Qantas Airways Limited (ASX: QAN).

    Can these ASX 200 shares do it all again in 2023? Let’s take a look at what analysts are saying.

    A2 Milk

    Unfortunately, as things stand, brokers appear to believe that the A2 Milk share price has peaked for the time being.

    For example, the most positive broker that I’m aware of is Bell Potter. However, while its analysts currently have a buy rating on the company’s shares, their price target of $6.80 is a touch below where its shares trade today.

    Though, a stronger than expected update in February when A2 Milk releases its half year results could force Bell Potter and other brokers to rethink their valuations and recommendations.

    Qantas

    Things are looking comparatively better for the Qantas share price in 2023 according to analysts.

    Goldman Sachs believes the market is severely undervaluing its shares given its very positive performance and outlook. The broker has a conviction buy rating and $8.20 price target on its shares.

    Elsewhere, Morgans has an add rating and $8.50 price target and Morgan Stanley has an overweight rating and $9.00 price target. These three price targets imply potential upside of at least 36% for the ASX 200 share over the next 12 months.

    In respect to the Morgans recommendation, its analysts commented:

    The discount being applied to QAN is unwarranted, in our view. Solid value exists in QAN given we expect further EBITDA growth over FY24/25 and think pent-up demand to travel will underpin a healthy demand environment for some time.

    The post Can these 2 ASX 200 shares crush the market again in 2023? appeared first on The Motley Fool Australia.

    FREE Investing Guide for Beginners

    Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…

    For over a decade, we’ve been helping everyday Aussies get started on their journey.

    And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.

    Yes, Claim my FREE copy!
    *Returns as of November 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/30p4Eae